Cost-utility of treatment of the patients with Thalassemia Major in Iran

Apply

Cost-utility of treatment of the patients with Thalassemia Major in Iran

Journal Title: Khoon - Year 2019, Vol 15, Issue 4

Abstract

Cost-utility of treatment of the patients with Thalassemia Major in Iran Emamgholipour S.1, Ahmadi B.1, Rajabi A.2, Azarkeivan A.3,4, Ebrahimi M.3,4, Esmaeilzadeh F.5 1School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 2Golestan University of Medical Sciences, Gorgan, Iran 3Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran 4Adult Thalassemia Clinic, Tehran, Iran 5Department of Public Health, School of Public Health, Maragheh University of Medical Sciences, Maragheh, Iran Abstract Background and Objectives Thalassemia major is an autosomal recessive disease with serious morbidity, mortality and pathology. Due to today’s therapeutic advances, the life expectancy of thalassemia patients has significantly increased. As a result, thalassemia patients need lifelong care, but caring for patients with thalassemia causes a lot of costs. Therefore, being aware of the costs and effectiveness of the treatments is essential for controlling the costs and providing effective treatments. Materials and Methods In this cross-sectional descriptive study, a bottom-up method was used to estimate the treatment costs for thalassemia patients and all the costs were estimated over a one-year period (2015). The number of QALYs created by treatment was also extracted using the EQ5D questionnaire, and eventually, the Markov model was used to calculate the costs and effectiveness for patients’ longevity. Results Treatment for any patients with thalassemia major costs $ 8,321.8 per year. Applying a 3% discount rate, we estimated that each patient lifelong treatment costs $ 147,098.4, which would results in 11.8 QALYs. Hence, the cost per QALY would be $ 12,466,0. Conclusions Treating the patients with thalassemia major, despite its cost effectiveness, might cost a lot so that the treatment of the patients in the fourth decade of their lives may even reach the cost-effectiveness threshold. Therefore, increasing the costs in the field of patient screening and prevention of the birth of patients with thalassemia major seems to be useful. Key words: Cost-Benefit Analysis, beta-Thalassemia, Iran Received: 30 Apr 2018 Accepted:14 Aug 2018 Correspondence: Esmaeilzadeh F., PhD in Health Economics. Assistant Professor of Department of Public Health, School of Public Health, Maragheh University of Medical Sciences. Postal Code: 5515878151, Maragheh, Iran. Tel: (+9841) 37256926; Fax: (+9841) 37256901 E-mail: firooz.esmaeilzadeh@gmail.com

Authors and Affiliations

S. Emamgholipour, B. Ahmadi, A. Rajabi, A Azarkeivan, M. Ebrahimi, F. Esmaeilzadeh

Keywords

In vitro differentiation of human umbilical vein mesenchymal <br /> stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green<br />

In vitro differentiation of human umbilical vein mesenchymal stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green Raufi A.1, Amini A.1, Azadbakht M.1, Aboozari M.2, Fathi F. 3...

EP ID EP522334
DOI -
Views 95
Downloads 0